Amarin Corporation Reports 8% Revenue Growth but Net Loss of $14.1 Million in Q2 2025

Amarin Corporation plc reported its financial results for the second quarter of 2025, revealing a total revenue of $72.7 million, an increase of 8% from $67.5 million in the same period last year. The growth was primarily driven by a significant rise in licensing and royalty revenue, which reached $26.1 million, up from $20.0 million in the prior year, largely due to a $25 million upfront payment from a new licensing agreement with Recordati. However, product revenue from VASCEPA, the company’s primary product, saw a decline, totaling $46.6 million compared to $47.5 million in the previous year, reflecting challenges in the U.S. market due to increased generic competition.

In terms of profitability, Amarin reported a net loss of $14.1 million for the quarter, a significant decline from a net income of $1.5 million in the same quarter of 2024. The loss was attributed to increased operating expenses, including a $22.8 million restructuring charge related to the global restructuring plan announced in June 2025, which aims to streamline operations following the Recordati agreement. Total operating expenses for the quarter rose to $66.3 million, compared to $43.3 million in the prior year, driven by higher general and administrative costs.

Operationally, Amarin's U.S. product revenue decreased to $36.5 million from $43.8 million, reflecting a 17% drop in market share from approximately 59% to 43% due to the entry of generic competitors. In contrast, the company reported a notable increase in European sales, with product revenue rising to $6.6 million from $3.5 million year-over-year. The company also recorded $3.5 million in revenue from collaboration partners, indicating a growing international presence.

As of June 30, 2025, Amarin's total assets stood at $670.1 million, with cash and cash equivalents of $147.9 million and short-term investments of $150.8 million. The company has no outstanding debt, which positions it favorably for future operations. Looking ahead, Amarin remains focused on expanding VASCEPA's market presence globally while navigating the challenges posed by generic competition in the U.S. The company anticipates that its restructuring efforts will yield annual cost savings of approximately $70 million, primarily through the elimination of commercial roles in Europe, as it aims to enhance operational efficiency and drive growth.